525
Views
6
CrossRef citations to date
0
Altmetric
Classical systemic treatment

Mycophenolate mofetil and enteric-coated mycophenolate sodium in the treatment of pemphigus vulgaris and pemphigus foliaceus

, , &
Pages 67-72 | Received 21 Nov 2013, Accepted 31 Dec 2013, Published online: 13 Feb 2014

References

  • Scully C, Challacombe SJ. Pemphigus vulgaris: update on etiopathogenesis, oral manifestations, and management. Crit Rev Oral Biol Med. 2002;13:397–408
  • Bektas M, Jolly P, Rubenstein DS. Apoptotic pathways in pemphigus. Dermatol Res Pract. 2010;2010:456841. doi: 10.1155/2010/456841. Epub 2010 Jun 15
  • Margolis DJ. A randomized trial and the treatment of pemphigus vulgaris. J Investig Dermatol. 2010;130:1964–6
  • Bongiorno MR, Pistone G, Doukaki S, Aricò M. Enteric-coated mycophenolate sodium in the treatment of refractory pemphigus. Int J Dermatol. 2010;49:693–9
  • Hofmann SC, Kautz O, Hertl M, et al. Results of a survey of German dermatologists on the therapeutic approaches to pemphigus and bullous pemphigoid. J German Soc Dermatol. 2009;7:227–33
  • Orvis AK, Wesson SK, Breza TS Jr, et al. Mycophenolate mofetil in dermatology. J Am Acad Dermatol. 2009;60:183–99
  • Enk AH, Knop J. Mycophenolate is effective in the treatment of pemphigus vulgaris. Archiv Dermatol. 1999;135:54–6
  • Marzano AV, Dassoni F, Caputo R. Treatment of refractory blistering diseases with mycophenolic acid. J Dermatol Treat. 2006;17:370–6
  • Beissert S, Werfel T, Frieling U, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Archiv Dermatol. 2006;142:1447–54
  • Beissert S, Mimouni D, Kanwar AJ, et al. Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. J Investig Dermatol. 2010;130:2041–8
  • Esmaili N, Chams-Davatchi C, Valikhani M, et al. Treatment of pemphigus vulgaris with mycophenolate mofetil as a steroid-sparing agent. Eur J Dermatol. 2008;18:159–64
  • Bredlich RO, Grundmann-Kollmann M, Behrens S, et al. Mycophenolate mofetil monotherapy for pemphigus vulgaris. Br J Dermatol. 1999 Nov;141(5):934
  • Grundmann-Kollmann M, Korting HC, Behrens S, et al. Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases. J Am Acad Dermatol. 1999;40:957–60
  • Nousari HC, Sragovich A, Kimyai-Asadi A, et al. Mycophenolate mofetil in autoimmune and inflammatory skin disorders. J Am Acad Dermatol. 1999;40:265–8
  • Katz KH, Marks JG Jr, Helm KF. Pemphigus foliaceus successfully treated with mycophenolate mofetil as a steroid-sparing agent. J Am Acad Dermatol. 2000;42:514–15
  • Mimouni D, Anhalt GJ, Cummins DL, et al. Treatment of pemphigus vulgaris with mycophenolate mofetil. Archiv Dermatol. 2003;139:739–42
  • Powell AM, Albert S, Al Fares S, et al. An evaluation of the usefulness of mycophenolate mofetil in pemphigus. Br J Dermatol. 2003;149:138–45
  • Sarma N, Ghosh S. Mycophenolate mofetil as adjuvant in pemphigus vulgaris. Ind J Dermatol, Venereol Leprol. 2007;73:348–50
  • Chams-Davatchi C, Nonahal Azar R, Daneshpazooh M, et al. Open trial of mycophenolate mofetil in the treatment of resistant pemphigus vulgaris. Annales de Dermatologie et de Vénéréologie. 2002;129:23–5
  • Strowd LC, Taylor SL, Jorizzo JL, Namazi MR. Therapeutic ladder for pemphigus vulgaris. emphasis on achieving complete remission. J Am Acad Dermatol. 2011;64:490–4
  • Baskan EB, Yilmaz M, Tunali S, Saricaoglu H. Efficacy and safety of long-term mycophenolate sodium therapy in pemphigus vulgaris. J Euro Acad Dermatol Venereol. 2009;23:1432–4
  • Jessop S, Khumalo NP. Pemphigus: a treatment update. Am J Clin Dermatol. 2008;9:147–54
  • Harman KE, Albert S, Black MM. Guidelines for the management of pemphigus vulgaris. Br J Dermatol. 2003;149:926–37
  • Chams-Davatchi C, Esmaili N, Daneshpazhooh M, et al. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol. 2007;57:622–8
  • Martin LK, Werth V, Villanueva E, et al. Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD006263. doi: 10.1002/14651858.CD006263.pub2
  • Yokoyama T, Amagai M. Immune dysregulation of pemphigus in humans and mice. J Dermatol. 2010;37:205–13
  • Akhyani M, Chams-Davatchi C, Hemami MR, Fateh S. Efficacy and safety of mycophenolate mofetil vs. methotrexate for the treatment of chronic plaque psoriasis. J Euro Acad Dermatol Venereol. 2010;24:1447–51
  • Villarroel MC, Hidalgo M, Jimeno A. Mycophenolate mofetil: an update. Drugs Today. 2009;45:521–32
  • Salvadori M, Holzer H, de Mattos A, et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transpl. 2003;4:231–6
  • Groves RW. Pemphigus: a brief review. Clin Med. 2009;9:371–5
  • Yeh SW, Ahmed B, Sami N, et al. Blistering disorders: diagnosis and treatment. Dermatol Therap. 2003;16:214–3
  • Engineer L, Bhol KC, Ahmed AR. Analysis of current data on the use of intravenous immunoglobulins in management of pemphigus vulgaris. J Am Acad Dermatol. 2000;43:1049–57

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.